Positive Outlook for LENZ Therapeutics: Buy Rating Affirmed Amid Regulatory Progress and Strategic Positioning

William Blair analyst Lachlan Hanbury Brown has reiterated their bullish stance on LENZ stock, giving a Buy rating yesterday.

Lachlan Hanbury Brown has given his Buy rating due to a combination of factors including the steady progress of LENZ Therapeutics’ LNZ100 NDA review by the FDA, which has faced no delays or interruptions. The company has successfully completed its midcycle review and is advancing towards a late-cycle review, indicating a positive regulatory trajectory.
Additionally, the company’s commercial preparations are on track, with marketing materials ready and a sales team being assembled ahead of the anticipated product launch. The strategic decisions, such as confirming the U.S. as the country of origin for LNZ100, which ensures it is duty-free, further strengthen the company’s position. The ongoing EyeAmSelective campaign has also generated significant interest, supporting the company’s outreach efforts. These factors, combined with the product’s strong market potential and minimal competition, underpin the Buy rating.

In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $60.00 price target.